Why the study?
Do SGLT2 inhibitors improve cardiovascular outcomes and mortality in patients with heart failure?
Do SGLT2 inhibitors improve cardiovascular outcomes and mortality in patients with heart failure?
SGLT2 inhibitors significantly reduce cardiovascular and all-cause mortality in patients with heart failure without increasing serious adverse events.
Answers are grounded in this paper and cite their sources.
Supports SGLT2 inhibitor use to reduce mortality in HF; confirms benefit with trend in HFpEF.
SGLT2 inhibitors significantly improve cardiovascular outcomes including cardiovascular and all-cause mortality in patients with HF without an increased risk of serious adverse events. A trend towards benefit was observed in patients with HF with preserved ejection fraction.
No takes yet. Share an insight, caveat, or question.
Butler et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: